World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
33250
World Ranking
16918
National Ranking
888

Kurt Miller publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Kurt Miller sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 699 publications — 81st percentile

81% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Kurt Miller D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Kurt Miller sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 80 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Kurt Miller is affiliated with Charité - University Medicine Berlin in Germany. Their research primarily spans the field of Medicine with a particular focus on several subfields, including Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Surgery, Oncology, and Urology.

Their research topics notably cover:

  • Prostate Cancer Treatment and Research
  • Radiopharmaceutical Chemistry and Applications
  • Prostate Cancer Diagnosis and Treatment
  • Bladder and Urothelial Cancer Treatments
  • Urinary Bladder and Prostate Research
  • Cancer Immunotherapy and Biomarkers
  • Pelvic floor disorders treatments

Miller has contributed to significant research outputs over the years. Some of the recent papers include:

  • Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States (2020) published in Clinical Genitourinary Cancer
  • Pasotuxizumab, a Bite ® Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings (2020) published in Immunotherapy
  • Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer (2022) published in JAMA Oncology
  • Transurethral en bloc submucosal hydrodissection vs conventional resection for resection of non-muscle-invasive bladder cancer (HYBRIDBLUE): a randomised, multicentre trial (2020) published in British Journal of Urology
  • Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer (2023) published in EClinicalMedicine

Their frequent co-authors include:

  • Celestia S. Higano
  • Laura Wiemer
  • Fred Saad
  • Bertrand Tombal
  • Oliver Sartor

In terms of publication venues, Miller has consistently contributed to:

  • Aktuelle Urologie
  • Journal of Clinical Oncology
  • Prostate Cancer and Prostatic Diseases
  • Journal of Clinical Medicine
  • Therapeutics and Clinical Risk Management

Best Publications

  • Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

    Howard I. Scher;Karim Fizazi;Fred Saad;Mary-Ellen Taplin

  • Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

    Tomasz M Beer;Andrew J Armstrong;Dana E Rathkopf;Yohann Loriot

  • Phase III Postoperative Adjuvant Radiotherapy After Radical Prostatectomy Compared With Radical Prostatectomy Alone in pT3 Prostate Cancer With Postoperative Undetectable Prostate-Specific Antigen: ARO 96-02/AUO AP 09/95

    Thomas Wiegel;Dirk Bottke;Ursula Steiner;Alessandra Siegmann

  • Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

    Charles J. Ryan;Matthew R. Smith;Karim Fizazi;Fred Saad

  • Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer : results of a phase 3, randomised, placebo-controlled trial.

    Matthew R Smith;Fred Saad;Robert Coleman;Neal Shore

  • Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma.

    Annika Schaefer;Monika Jung;Hans-Joachim Mollenkopf;Ina Wagner

  • The ileal neobladder

    Hautmann Re;Egghart G;Frohneberg D;Miller K

  • Adjuvant Radiotherapy Versus Wait-and-See After Radical Prostatectomy: 10-year Follow-up of the ARO 96–02/AUO AP 09/95 Trial

    Thomas Wiegel;Detlef Bartkowiak;Dirk Bottke;Claudia Bronner

  • Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.

    Tomasz M. Beer;Andrew J Armstrong;Dana E Rathkopf;Yohann Loriot

  • Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Matthew Smith;Chris Parker;Fred Saad;Kurt Miller

  • Sarcosine in Urine after Digital Rectal Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours

    Florian Jentzmik;Carsten Stephan;Kurt Miller;Mark Schrader

  • Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial

    Fred Saad;Joan Carles;Silke Gillessen;Axel Heidenreich

  • Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations

    E. David Crawford;Axel Heidenreich;Axel Heidenreich;Nathan Lawrentschuk;Bertrand Tombal

  • Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

    Hubert Kübler;Birgit Scheel;Ulrike Gnad-Vogt;Kurt Miller

  • A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study

    James A. Thomas;Andrea Tubaro;Neil Barber;Frank d’Ancona

  • Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer

    Karim S. Fizazi;Celestia S. Higano;Joel B. Nelson;Martin Gleave

  • Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time

    Matthew R. Smith;Fred Saad;Stephane Oudard;Neal Shore

  • 180-W XPS GreenLight Laser Vaporisation Versus Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 6-Month Safety and Efficacy Results of a European Multicentre Randomised Trial—The GOLIATH Study

    Alexander Bachmann;Andrea Tubaro;Neil Barber;Frank d’Ancona

  • Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

    Matthew Smith;Johann De Bono;Cora Sternberg;Sylvestre Le Moulec

  • Systemic therapy in metastatic renal cell carcinoma

    Jens Bedke;Thomas Gauler;Viktor Grünwald;Axel Hegele

Frequent Co-Authors

Fred Saad
Fred Saad University of Montreal
Carsten Stephan
Carsten Stephan Charité - University Medicine Berlin
Cora N. Sternberg
Cora N. Sternberg Cornell University
Karim Fizazi
Karim Fizazi University of Paris-Saclay
Celestia S. Higano
Celestia S. Higano University of Washington
Bertrand Tombal
Bertrand Tombal Université Catholique de Louvain
Neal D. Shore
Neal D. Shore Carolina Urologic Research Center
Axel Heidenreich
Axel Heidenreich University of Cologne
Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
Peter F.A. Mulders
Peter F.A. Mulders Radboud University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring a future in healthcare beyond traditional medicine, many flexible online degree options can help you enter or advance in growing fields. For those interested in patient care without lengthy admissions processes, consider enrolling in a nursing school that does not require teas test. These programs streamline the path to becoming a Registered Nurse and open doors to meaningful roles.

Administrative leadership is also a vital part of healthcare. An online healthcare administration associate degree online can quickly prepare you for opportunities in hospital or clinic management—often in as little as two years. If you’re a working nurse with an associate degree, ADN to MSN bridge programs offer a direct, accelerated path to advanced practice and leadership. Explore your options with adn to msn bridge programs.

Another emerging field is nutrition, pivotal for preventive health and wellness. Launch your career by enrolling in an online bachelor's degree in nutrition, opening diverse pathways in public health, wellness coaching, and clinical settings.

Best Scientists Citing Kurt Miller

Trending Scientists

Recently Published Articles